Furthermore, the results of a large-scale systematic review and meta-analysis have shown that, in patients with ischemic stroke or transient ischemic attack treated with clopidogrel, carriers of genetic polymorphisms, especially variants of CYP2C19, are at higher risk of stroke and vascular events than non-carriers [19]. The gene discussed is CYP2C19; the disease is ischemic stroke.